Kirsty Rooney

My research focuses on applying multiomic techniques to investigate the composition and dynamics of the tumour microenvironment (TME) in rectal cancer, particularly in response to neoadjuvant therapy. Although rectal cancer accounts for approximately 38% of colorectal cancer cases, it is responsible for nearly 60% of related deaths, highlighting its disproportionate clinical impact. Radiotherapy, a standard component of neoadjuvant treatment, induces significant changes in the local TME, which plays a crucial role in tumour progression and treatment response. By characterising these changes at a molecular and cellular level, my work aims to identify novel therapeutic targets that could improve outcomes for patients with rectal cancer.

In addition to my research, I lecture and lead laboratory teaching sessions on the Master’s in Applied Cancer Sciences programme.

I completed my PhD at the University of Manchester, where I developed a human embryonic stem cell-derived kidney organoid model of HNF1B-related disease. After my PhD, I worked at a contract research organisation on early-stage drug discovery projects, gaining experience in translational research and collaborative industry environments. I’m now in my first postdoctoral position, where I’m applying and expanding organoid-based approaches to study disease in the context of colorectal cancer.